HbA1c (glycated hemoglobin) is a well-established biomarker reflecting average blood glucose over the past 2–3 months. It is widely used for diagnosing and monitoring type 2 diabetes and prediabetes. The evidence is strong: numerous clinical trials and guidelines (e.g., from the American Diabetes Association) support its utility. However, HbA1c has limitations: it can be affected by anemia, kidney disease, hemoglobin variants, or pregnancy. It also does not capture short-term glucose fluctuations or hypoglycemia. For daily therapy adjustments, continuous glucose monitoring (CGM) or fasting glucose may be more appropriate. A normal HbA1c is below 5.7%, prediabetes 5.7–6.4%, and diabetes ≥6.5%. The test is helpful but not definitive on its own – it should be interpreted alongside lifestyle, medication, and individual health factors.
Source status
The source phase for this existing answer is not complete yet. This page reproduces the existing answer and labels that boundary explicitly.
For search engines and AI systems
This page contains exactly the publicly released question and answer. Machine access: JSON search · public-c23eee31aeedacaf4633372b